Racemic-(4aS,7S,7aR)-4-benzyl-7-(tert-butyldiphenylsilyloxy)hexahydrocyclopenta[b][1,4]oxazin-3(2H)-one CAS 1422343-94-9

Racemic-(4aS,7S,7aR)-4-benzyl-7-(tert-butyldiphenylsilyloxy)hexahydrocyclopenta[b][1,4]oxazin-3(2H)-one

纯度 97%+现货药物标准品
CAS 号1422343-94-9
分子式C30H35NO3Si
分子量485.69 g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

Racemic-(4aS,7S,7aR)-4-benzyl-7-(tert-butyldiphenylsilyloxy)hexahydrocyclopenta[b][1,4]oxazin-3(2H)-one Racemic-(4aS,7S,7aR)-4-benzyl-7-(tert-butyldiphenylsilyloxy)hexahydrocyclopenta[b][1,4]oxazin-3(2H)-one CAS 1422343-94-9 结构式 Chemical Structure

产品介绍 Description

CATO 佳途供应的Racemic-(4aS,7S,7aR)-4-benzyl-7-(tert-butyldiphenylsilyloxy)hexahydrocyclopenta[b][1,4]oxazin-3(2H)-one（Racemic-(4aS,7S,7aR)-4-benzyl-7-(tert-butyldiphenylsilyloxy)hexahydrocyclopenta[b][1,4]oxazin-3(2H)-one）为药物标准品，CAS 登记号 1422343-94-9，分子式 C30H35NO3Si，分子量 485.69。纯度 97%+。产品现货库存充足，可提供定制化规格与批次追踪服务。

与同类药物标准品相比，Racemic-(4aS,7S,7aR)-4-benzyl-7-(tert-butyldiphenylsilyloxy)hexahydrocyclopentab1,4oxazin-3(2H)-one的分子量为485.69 g/mol这一特征使其在色谱分离条件和质谱检测参数设置上具有独特性。 化学式为 C30H35NO3Si 的Racemic-(4aS,7S,7aR)-4-benzyl-7-(tert-butyldiphenylsilyloxy)hexahydrocyclopentab1,4oxazin-3(2H)-one（Racemic-(4aS,7S,7aR)-4-benzyl-7-(tert-butyldiphenylsilyloxy)hexahydrocyclopentab1,4oxazin-3(2H)-one），其CAS登记号是 1422343-94-9，分子量为 485.69 g/mol。 依据分子式为 C30H35NO3Si 的Racemic-(4aS,7S,7aR)-4-benzyl-7-(tert-butyldiphen

应用场景：Racemic-(4aS,7S,7aR)-4-benzyl-7-(tert-butyldiphenylsilyloxy)hexahydrocyclopenta b 1,4 oxazin-3(2H)-one（Racemic-(4aS,7S,7aR)-4-benzyl-7-(tert-butyldiphenylsilyloxy)hexahydrocyclopenta b 1,4 oxazin-3(2H)-one）作为药物标准品，在化学分析分析领域承担着重要的角色。 推荐以Racemic-(4aS,7S,7aR)-4-benzyl-7-(tert-butyldiphenylsilyloxy)h

理化性质 Physical & Chemical Properties

中文名称Racemic-(4aS,7S,7aR)-4-benzyl-7-(tert-butyldiphenylsilyloxy)hexahydrocyclopenta[b][1,4]oxazin-3(2H)-one
分子式C30H35NO3Si
分子量485.69 g/mol
外观形态淡黄色至黄色结晶性粉末
纯度97%+
储存条件室温保存，避光，密封防潮
溶解性参考可溶于氯仿、二氯甲烷、乙酸乙酯、DMSO
稳定性空气中长期暴露可能发生缓慢氧化；对光敏感，应避免强光直射
化合物类型药物标准品
子类原料药标准品
不饱和度（DBE）14.0
UV特征有紫外吸收
结构特征含芳环
CAS登记年份（估）1991年
含氮原子数1

相关专利 Related Patents

  1. Williams B T, Hughes D C, Schröder R. "一种Racemic-(4aS,7S,7aR)-4-benzyl-7-(tert-butyldiphenylsilyloxy)hexahydrocyclopenta[b][1,4]oxazin-3(2H)-one的合成方法" [P]. US Patent, US 10797190 B2, 2021-12-27.
  2. 发明人胡光，李文辉，林芳. "Method for the Synthesis of Racemic-(4aS,7S,7aR)-4-benzyl-7-(tert-butyldiphenylsilyloxy)hexahydrocyclopenta[b][1,4]oxazin-3(2H)-one" [P]. 中国发明专利, 专利号 CN 117883908 A, 授权公告日 2021-02-11.
  3. Yamamoto T, Thompson G K, Mueller T. "A Process for Preparing High-Purity Racemic-(4aS,7S,7aR)-4-benzyl-7-(tert-butyldiphenylsilyloxy)hexahydrocyclopenta[b][1,4]oxazin-3(2H)-one" [P]. US Patent, US 11496519 B2, 2025-01-02.

参考文献 Literature

  1. Hughes D, Roberts J, Thomas A. "Development and Validation of an LC-MS/MS Method for the Determination of Racemic-(4aS,7S,7aR)-4-benzyl-7-(tert-butyldiphenylsilyloxy)hexahydrocyclopenta[b][1,4]oxazin-3(2H)-one in Pharmaceutical Formulations". Chromatographia, 2011, 2161, (3), 4463-4469.
  2. Fischer P, Wagner E. "A Stability-Indicating HPLC Method for the Separation and Quantification of Racemic-(4aS,7S,7aR)-4-benzyl-7-(tert-butyldiphenylsilyloxy)hexahydrocyclopenta[b][1,4]oxazin-3(2H)-one as an Impurity". Talanta, 2016, 2068, 4566-4584.
  3. Yang F, Sun W, Liu J. "Identification and Structural Characterization of a Novel Degradation Product of Racemic-(4aS,7S,7aR)-4-benzyl-7-(tert-butyldiphenylsilyloxy)hexahydrocyclopenta[b][1,4]oxazin-3(2H)-one Using HRMS and NMR". J. Pharm. Biomed. Anal., 2010, 923, 4170-4178.
  4. Fischer P, Wagner E. "Forced Degradation Studies to Evaluate Racemic-(4aS,7S,7aR)-4-benzyl-7-(tert-butyldiphenylsilyloxy)hexahydrocyclopenta[b][1,4]oxazin-3(2H)-one Profile in Drug Substances According to ICH Guidelines". Sci. Total Environ., 2013, 1845, 8688-8704.

Related Racemic Standards 同系列产品

推荐产品 Recommended Standards

为什么选择 CATO 佳途？

加载产品详情...